BioAtla, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that BioAtla, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2021 | $300.0K | Mar 23, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.61M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($69.78M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($123.46M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($106.48M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($95.40M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($26.88M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($29.86M) | Feb 28, 2022 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.31M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($73.94M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($129.69M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($108.14M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($96.44M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($30.10M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($28.27M) | Feb 28, 2022 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $43.57M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $63.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $103.73M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $79.35M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $58.27M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $19.93M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $25.92M | Feb 28, 2022 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($48.20M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($71.94M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($104.02M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($90.42M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($62.21M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($36.33M) | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | ($9.65M) | Feb 28, 2022 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $13.83M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $52.42M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $119.66M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $225.74M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $254.42M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $244.94M | Feb 28, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.02M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $38.16M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $48.99M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $45.40M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $43.60M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $34.96M | Feb 28, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($36.19M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $14.27M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $70.67M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $180.34M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $210.82M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $209.97M | Feb 28, 2022 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($545.65M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($486.04M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($416.26M) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | ($292.80M) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | ($186.32M) | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | ($90.92M) | Feb 28, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.12M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $49.05M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $111.47M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | $215.51M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | $244.98M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | $238.61M | Feb 28, 2022 |
| FY2021 | Dec 31, 2019 | $3.70M | Feb 28, 2022 |
| FY2021 | Dec 31, 2018 | $10.86M | Feb 28, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (1) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | (2) | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | (2) | Mar 23, 2023 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 63.46M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 58.10M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 48.08M | Mar 28, 2025 |
| FY2023 | Dec 31, 2022 | 46.34M | Mar 26, 2024 |
| FY2022 | Dec 31, 2021 | 35.80M | Mar 23, 2023 |
| FY2021 | Dec 31, 2020 | 32.17M | Feb 28, 2022 |